Biomarkers for the diagnosis of deep vein thrombosis

Coleman, Dawn M.; Wakefield, Thomas W.

doi:10.1517/17530059.2012.692674

Cited by 22 publications

(18 citation statements)

References 31 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Establishing suitable biomarkers for DVT diagnosis is of interest, because for now ultrasound remains the best diagnostic method but is not always reliable. 85 Circulating nucleosomes and markers of neutrophil activation (elastase-a1-antitrypsin and MPO) are significantly increased in persons with DVT, compared with patients with symptoms but lack of confirmed DVT diagnosis. 86,87 Plasma DNA positively correlates with VWF and negatively correlates with levels of ADAMTS13, 87 supporting a relationship between NETs and VWF in DVT.…”

Section: Nets In Human Thrombosismentioning

confidence: 98%

Thrombosis: tangled up in NETs

Martinod

Wagner

2014

Blood

696

622

View full text Add to dashboard Cite

The contributions by blood cells to pathological venous thrombosis were only recently appreciated. Both platelets and neutrophils are now recognized as crucial for thrombus initiation and progression. Here we review the most recent findings regarding the role of neutrophil extracellular traps (NETs) in thrombosis. We describe the biological process of NET formation (NETosis) and how the extracellular release of DNA and protein components of NETs, such as histones and serine proteases, contributes to coagulation and platelet aggregation. Animal models have unveiled conditions in which NETs form and their relation to thrombogenesis. Genetically engineered mice enable further elucidation of the pathways contributing to NETosis at the molecular level. Peptidylarginine deiminase 4, an enzyme that mediates chromatin decondensation, was identified to regulate both NETosis and pathological thrombosis. A growing body of evidence reveals that NETs also form in human thrombosis and that NET biomarkers in plasma reflect disease activity. The cell biology of NETosis is still being actively characterized and may provide novel insights for the design of specific inhibitory therapeutics. After a review of the relevant literature, we propose new ways to approach thrombolysis and suggest potential prophylactic and therapeutic agents for thrombosis.

show abstract

Section: Nets In Human Thrombosismentioning

confidence: 98%

Thrombosis: tangled up in NETs

Martinod

Wagner

2014

Blood

696

622

View full text Add to dashboard Cite

show abstract

“…However, diagnosis cannot be based only on clinical presentation due to the lack of sensitivity and specificity of signs and symptoms (13) . Historically, the diagnosis of acute venous thromboembolism (DVT and PE) had depend primarily on imaging modalities including duplex ultrasound, helical CT scans, and venography, to establish the diagnosis of VTE.…”

Section: Discussionmentioning

confidence: 99%

Soluble P-Selectin Level in Patients with Deep Venous Thrombosis

Saadeldin

El-Sakhawy

Shalaby

et al. 2018

Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Venous thromboembolic disease (VTE) remains a significant source of morbidity and mortality. As non-specific subjective complaints and a lack of objective clinical examination findings complicate the diagnosis of both deep venous thrombosis (DVT) and pulmonary embolism. Objective diagnostic testing is required to confirm or exclude the presence of venous thromboembolism before subjecting patients to unnecessary long-term anticoagulation. Aim of the Work: This study was aimed to measure the level of soluble P-selectin (sPsel) in Egyptian patients with DVT and asses its diagnostic value in relation to other clinical data and radiological examination. Subjects and Methods: This study was carried out on 80 individuals, attending Ain Shams University Hospitals between October 2015 and March 2016 after Ethical committee approval. They were divided into two groups.: Group I, 50 patients who were positive for DVT by duplex ultrasound. They were 41 males and 9 females. Their ages ranged 20-77 years, with a mean of 46.20 ± 11.78 years. They were 41 (82%) males and 9 (18%) females, with a male to female ratio of 4.55:1. Group II: 30 healthy subjects with no clinical signs, symptoms, or history of DVT. They were 23 (76.7%) males and 7 (23.3%) females, with a male to female ratio of 3.28:1. Results: There was a highly significant difference between patients (group I) and controls (group II) as regards P-selectin, the best cut off was70.5 ng/ml with 98% sensitivity, 100% specificity, a NPV of 96.8% and a PPV of 100%. Conclusion: Diagnostic cutoff levels of P-selectin in cases with DVT is 70.5 mg/L that can safely differentiate patients who are free from DVT from others who are positive for DVT or those who would eventually develop thrombosis regardless their primary duplex ultrasound scanning results. Recommendations: As our study recommends the use of serum P-selectin as diagnostic biomarker in DVT alone; in addition to the newly estimated cutoff levels for these biomarker, further studies on larger number of cases are needed for more evaluation of these cutoff values and to establish whether they could be used to guide anticoagulation therapy when duplex ultrasound is unavailable.

show abstract

“…Coleman et al demonstrated that inhibition of both E-selectin and P-selectin is an effective strategy to reduce venous thrombosis [12].…”

Section: E-selectinmentioning

confidence: 99%

“…The aim of our review was to analyze the currently used biomarkers involved in the pathophysiology and diagnosis of venous thrombosis. They are very important not only in venous thrombogenesis but also to target the length of appropriate anticoagulation treatment and to predict thrombus biological activity [12].…”

Section: Introductionmentioning

confidence: 99%

From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis

Anghel

Sascău

Radu

et al. 2020

IJMS

View full text Add to dashboard Cite

Venous thrombosis is a common and potentially fatal disease, because of its high morbidity and mortality, especially in hospitalized patients. To establish the diagnosis of venous thrombosis, in the last years, a multi-modality approach that involves not only imaging modalities but also serology has been evolving. Multiple studies have demonstrated the use of some biomarkers, such as D-dimer, selectins, microparticles or inflammatory cytokines, for the diagnosis and treatment of venous thrombosis, but there is no single biomarker available to exclusively confirm the diagnosis of venous thrombosis. Considering the fact that there are some issues surrounding the management of patients with venous thrombosis and the duration of treatment, recent studies support the idea that these biomarkers may help guide the length of appropriate anticoagulation treatment, by identifying patients at high risk of recurrence. At the same time, biomarkers may help predict thrombus evolution, potentially identifying patients that would benefit from more aggressive therapies. This review focuses on classic and novel biomarkers currently under investigation, discussing their diagnostic performance and potential benefit in guiding the therapy for venous thrombosis.

show abstract

Biomarkers for the diagnosis of deep vein thrombosis

Cited by 22 publications

References 31 publications

Thrombosis: tangled up in NETs

Thrombosis: tangled up in NETs

Soluble P-Selectin Level in Patients with Deep Venous Thrombosis

From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis

Contact Info

Product

Resources

About